Accelerating translational research through open innovation: Imperial/LMS Drug Discovery Hub Partners with opnMe® by Boehringer Ingelheim

We are excited to announce our partnership between the Imperial/LMS Drug Discovery Hub and opnMe® by Boehringer Ingelheim!

A Commitment to Open Science In alignment with their mission for open science, opnMe® has generously provided us with their entire set of high-quality, well-characterized molecules. These compounds, have now been integrated into our extensive compound library, which exceeds 60,000 molecules.

Enhancing Collaborative Research This strategic partnership expands access to valuable resources for our scientific community. By adding the opnMe® collection to our compound library, we empower researchers with the tools needed to advance their projects without financial barriers. These compounds are now available at no cost to our collaborators, enabling broader scientific exploration and collaboration.

Driving Translational Research Forward Together, Imperial/LMS Drug Discovery Hub and opnMe® are working to accelerate translational research by ensuring scientists have the resources to explore new hypotheses, validate biological targets, and contribute to impactful discoveries. Our shared goal is to enhance the accessibility of critical scientific tools while upholding the principles of open science.

Join Us in the Pursuit of Scientific Innovation We invite the scientific community to explore the expanded compound library and take advantage of these valuable resources.

Stay tuned for updates on our collaborative projects and ongoing efforts to support open-access research!